Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06BXT
|
|||
| Former ID |
DIB018434
|
|||
| Drug Name |
[3H]WIN55212-2
|
|||
| Synonyms |
131513-18-3; (5-methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone; (5-Methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino-[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone; [5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl](1-naphthyl)methanone; 134959-51-6; AC1Q5GBM; AC1L1KWZ; GTPL736; SCHEMBL3680086; CHEMBL283206; CTK4B9570; HQVHOQAKMCMIIM-UHFFFAOYSA-N
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C27H26N2O3
|
|||
| Canonical SMILES |
CC1=C(C2=C3N1C(COC3=CC=C2)CN4CCOCC4)C(=O)C5=CC=CC6=CC=CC=C65
|
|||
| InChI |
1S/C27H26N2O3/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28/h2-11,20H,12-17H2,1H3
|
|||
| InChIKey |
HQVHOQAKMCMIIM-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5455586, 7980529, 8153488, 29224726, 47440499, 47736729, 48185207, 49992235, 57322895, 77916045, 85209355, 103065245, 103086020, 103856313, 104309968, 117565771, 125335448, 128100014, 135062074, 135081343, 135651216, 137746913, 160832906, 162787888, 163397139, 163844312, 172858107, 175608138, 179293804, 189659184, 204432480, 229675402, 242084306, 249967136, 252492187
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Agonist | [2] |
| Cannabinoid receptor 2 (CB2) | Target Info | Agonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 736). | |||
| REF 2 | Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem. 1998 Jan;70(1):366-73. | |||
| REF 3 | Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol. 1995 Aug;48(2):352-61. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.